KR102657910B1 - 개선된 안정성, 강화된 면역원성과 감소된 반응원성을 갖는 면역원성 조성물 및 그의 제조 방법 - Google Patents

개선된 안정성, 강화된 면역원성과 감소된 반응원성을 갖는 면역원성 조성물 및 그의 제조 방법 Download PDF

Info

Publication number
KR102657910B1
KR102657910B1 KR1020207004735A KR20207004735A KR102657910B1 KR 102657910 B1 KR102657910 B1 KR 102657910B1 KR 1020207004735 A KR1020207004735 A KR 1020207004735A KR 20207004735 A KR20207004735 A KR 20207004735A KR 102657910 B1 KR102657910 B1 KR 102657910B1
Authority
KR
South Korea
Prior art keywords
antigen
delete delete
type
mixture obtained
hib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004735A
Other languages
English (en)
Korean (ko)
Other versions
KR20200042470A (ko
Inventor
쿠마르 라케시
인더 지트 샤르마
아닐 비얀카트라오 쉬토레
마노하 도다파네니
히트 죠티 샤르마
Original Assignee
세럼 인스티튜트 오브 인디아 프라이비트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 filed Critical 세럼 인스티튜트 오브 인디아 프라이비트 리미티드
Publication of KR20200042470A publication Critical patent/KR20200042470A/ko
Application granted granted Critical
Publication of KR102657910B1 publication Critical patent/KR102657910B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020207004735A 2017-07-18 2018-07-13 개선된 안정성, 강화된 면역원성과 감소된 반응원성을 갖는 면역원성 조성물 및 그의 제조 방법 Active KR102657910B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721025513 2017-07-18
IN201721025513 2017-07-18
PCT/IB2018/055180 WO2019016654A1 (en) 2017-07-18 2018-07-13 IMMUNOGENIC COMPOSITION WITH IMPROVED STABILITY, ENHANCED IMMUNOGENICITY, AND LESS REACTOGENICITY, AND PREPARATION METHOD THEREOF

Publications (2)

Publication Number Publication Date
KR20200042470A KR20200042470A (ko) 2020-04-23
KR102657910B1 true KR102657910B1 (ko) 2024-04-18

Family

ID=63556364

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004735A Active KR102657910B1 (ko) 2017-07-18 2018-07-13 개선된 안정성, 강화된 면역원성과 감소된 반응원성을 갖는 면역원성 조성물 및 그의 제조 방법

Country Status (21)

Country Link
US (1) US11179453B2 (enExample)
EP (1) EP3655024A1 (enExample)
JP (1) JP7404226B2 (enExample)
KR (1) KR102657910B1 (enExample)
CN (1) CN111032078A (enExample)
AU (1) AU2018302767B2 (enExample)
BR (1) BR112020000999A2 (enExample)
CA (1) CA3070039A1 (enExample)
CO (1) CO2020001765A2 (enExample)
EA (1) EA202090316A1 (enExample)
GE (1) GEP20227386B (enExample)
JO (1) JOP20180069B1 (enExample)
MX (1) MX2020000441A (enExample)
PE (1) PE20201443A1 (enExample)
PH (1) PH12020500133A1 (enExample)
SG (1) SG11202000224SA (enExample)
TW (1) TWI786153B (enExample)
UA (1) UA128204C2 (enExample)
UY (1) UY37811A (enExample)
WO (1) WO2019016654A1 (enExample)
ZA (1) ZA202000889B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101359953B1 (ko) * 2005-06-27 2014-02-21 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
AU2007224734C1 (en) 2006-03-10 2016-07-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Live attenuated Bordetella strains as a single dose vaccine against whooping cough
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
EP3697439A1 (en) * 2017-10-18 2020-08-26 Institut Pasteur de Lille Bordetella strains expressing serotype 3 fimbriae
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP3988290A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method for manufacturing a spectacle lens
EP3988288A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
EP3988289A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
WO2022114921A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법
MY208608A (en) * 2021-04-20 2025-05-20 Km Biologics Co Ltd Liquid sextuple vaccine composition
CN120826235A (zh) * 2023-03-16 2025-10-21 艾芬尼维克斯公司 免疫原性组合物
CN119799602A (zh) * 2025-03-17 2025-04-11 艾美坚持生物制药有限公司 一种破伤风梭状芽胞杆菌发酵培养基及培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046934A1 (en) * 2008-10-24 2010-04-29 Panacea Biotec Ltd. Combination vaccine with whole cell pertussis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000016I1 (de) 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
EP0833662B2 (en) * 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
BR9714980A (pt) 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
CN103585624A (zh) 2006-09-07 2014-02-19 葛兰素史密丝克莱恩生物有限公司 疫苗
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
EP3459562B1 (en) * 2011-01-05 2024-03-20 Bharat Biotech International Limited A combination heptavalent vaccine
JP6564367B2 (ja) * 2013-08-05 2019-08-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
BR112018005291A2 (pt) * 2015-09-16 2018-10-09 Lg Chemical Ltd composição para vacina combinada para dosagem múltipla

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046934A1 (en) * 2008-10-24 2010-04-29 Panacea Biotec Ltd. Combination vaccine with whole cell pertussis

Also Published As

Publication number Publication date
MX2020000441A (es) 2020-08-17
US20200206331A1 (en) 2020-07-02
UA128204C2 (uk) 2024-05-08
JOP20180069A1 (ar) 2019-01-18
JP7404226B2 (ja) 2023-12-25
SG11202000224SA (en) 2020-02-27
PH12020500133A1 (en) 2021-02-08
UY37811A (es) 2019-01-02
PE20201443A1 (es) 2020-12-10
ZA202000889B (en) 2021-06-30
KR20200042470A (ko) 2020-04-23
TWI786153B (zh) 2022-12-11
TW201919690A (zh) 2019-06-01
CO2020001765A2 (es) 2020-05-29
JP2020527571A (ja) 2020-09-10
AU2018302767B2 (en) 2025-04-10
US11179453B2 (en) 2021-11-23
CN111032078A (zh) 2020-04-17
JOP20180069B1 (ar) 2022-09-15
GEP20227386B (en) 2022-06-10
EA202090316A1 (ru) 2020-12-08
WO2019016654A1 (en) 2019-01-24
CA3070039A1 (en) 2019-01-24
EP3655024A1 (en) 2020-05-27
BR112020000999A2 (pt) 2020-07-14
AU2018302767A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
KR102657910B1 (ko) 개선된 안정성, 강화된 면역원성과 감소된 반응원성을 갖는 면역원성 조성물 및 그의 제조 방법
KR102822878B1 (ko) 감소된 용량의 불활성화된 폴리오바이러스를 포함하는 조합 백신 조성물 및 그의 제조 방법
RU2435609C2 (ru) КОМБИНИРОВАННЫЕ ВАКЦИНЫ С НИЗКОЙ ДОЗОЙ КОНЪЮГАТА Hib
JP2012506420A (ja) 全細胞百日咳を含む混合ワクチン
KR102607295B1 (ko) 다가 백신 조성물
EP4327820A1 (en) Liquid sextuple vaccine composition
EA047205B1 (ru) Состав полностью жидкой комбинированной вакцины с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ её получения
EA043311B1 (ru) Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
US11793869B2 (en) Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
JP2000511553A (ja) ボルデテラ・ペルツッシスの外膜タンパク質フラグメントを有してなるワクチン組成物
EA043682B1 (ru) Комбинированная вакцина и способ её производства (варианты)
OA21991A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
OA20569A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000